LLY

754.57

-0.24%↓

JNJ

178.08

-0.17%↓

ABBV

218.3

-0.8%↓

UNH

352.9

-0.29%↓

AZN

79.54

-1.96%↓

LLY

754.57

-0.24%↓

JNJ

178.08

-0.17%↓

ABBV

218.3

-0.8%↓

UNH

352.9

-0.29%↓

AZN

79.54

-1.96%↓

LLY

754.57

-0.24%↓

JNJ

178.08

-0.17%↓

ABBV

218.3

-0.8%↓

UNH

352.9

-0.29%↓

AZN

79.54

-1.96%↓

LLY

754.57

-0.24%↓

JNJ

178.08

-0.17%↓

ABBV

218.3

-0.8%↓

UNH

352.9

-0.29%↓

AZN

79.54

-1.96%↓

LLY

754.57

-0.24%↓

JNJ

178.08

-0.17%↓

ABBV

218.3

-0.8%↓

UNH

352.9

-0.29%↓

AZN

79.54

-1.96%↓

Search

10X Genomics Inc (Class A)

Closed

SectorHealthcare

12.64 -2.84

Overview

Share price change

24h

Current

Min

12.6

Max

12.79

Key metrics

By Trading Economics

Income

69M

35M

Sales

18M

173M

EPS

0.28

Profit margin

19.975

Employees

1,306

EBITDA

86M

47M

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+18.04% upside

Dividends

By Dow Jones

Next Earnings

28 Oct 2025

Market Stats

By TradingEconomics

Market Cap

50M

1.7B

Previous open

15.48

Previous close

12.64

News Sentiment

By Acuity

34%

66%

95 / 371 Healthcare

Technical Score

By Trading Central

Confidence

Bullish Evidence

10X Genomics Inc (Class A) Chart

Past performance is not a reliable indicator of future results.

Related News

12 Sept 2025, 22:41 UTC

Major Market Movers

GlucoTrack Stock Falls on Plans to Sell $3 Million Note

12 Sept 2025, 16:04 UTC

Major Market Movers

Upexi Shares Climb on Solana Gains

14 Sept 2025, 23:48 UTC

Market Talk

Oil Futures Mixed Amid Divergent Signals -- Market Talk

14 Sept 2025, 23:41 UTC

Market Talk

Gold Edges Lower on Likely Technical Correction -- Market Talk

14 Sept 2025, 23:38 UTC

Market Talk

China's Economic Activity Data May Continue Reflecting Slowdown -- Market Talk

14 Sept 2025, 23:13 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

14 Sept 2025, 23:13 UTC

Market Talk

Global Energy Roundup: Market Talk

14 Sept 2025, 23:13 UTC

Market Talk

Infratil May Need to Be More Aggressive With Asset Sales -- Market Talk

14 Sept 2025, 23:13 UTC

Market Talk

Global Equities Roundup: Market Talk

14 Sept 2025, 23:04 UTC

Market Talk

Aristocrat's Interactive Unit Appears in Safe Hands -- Market Talk

13 Sept 2025, 08:20 UTC

Market Talk
Earnings

Tech, Media & Telecom Roundup: Market Talk

12 Sept 2025, 20:50 UTC

Market Talk
Earnings

Tech, Media & Telecom Roundup: Market Talk

12 Sept 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

12 Sept 2025, 20:09 UTC

Earnings

Correction to Opendoor Is Sliding. Don't Call It a Meme Stock, Says New Chairman. -- Barrons.com

12 Sept 2025, 19:23 UTC

Market Talk

Oil Futures End Volatile Week With Moderate Gains -- Market Talk

12 Sept 2025, 19:16 UTC

Market Talk

Oil Futures End Volatile Week With Moderate Gains -- Market Talk

12 Sept 2025, 19:03 UTC

Market Talk

Natural Gas Futures Held Back By Plump Inventories -- Market Talk

12 Sept 2025, 18:59 UTC

Market Talk

Dollar Pares Gains as Economy Keeps Showing Signs of Cooling -- Market Talk

12 Sept 2025, 18:38 UTC

Market Talk
Earnings

Adobe Seen Reaching Turning Point in AI Cycle -- Market Talk

12 Sept 2025, 18:33 UTC

Market Talk

U.S. Oil Rig Count Rises By 2 to 416 -- Market Talk

12 Sept 2025, 18:22 UTC

Market Talk

Canada's Divergence With US On Capex Spending is 'Appalling' -- Market Talk

12 Sept 2025, 16:56 UTC

Market Talk

Renewable Fuels Association Calls for Nationwide E15 Following WASDE -- Market Talk

12 Sept 2025, 16:22 UTC

Earnings

Adobe Earnings Were 'Solid.' Long-Term Growth Concerns Remain. -- Barrons.com

12 Sept 2025, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

12 Sept 2025, 16:19 UTC

Acquisitions, Mergers, Takeovers

These Stocks Are Moving the Most Today: Warner Bros., Paramount Skydance, Tesla, Super Micro, Microsoft, Figure Technology, and More -- Barrons.com

12 Sept 2025, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

12 Sept 2025, 16:11 UTC

Earnings

Novartis Catches a 'Sell.' Goldman Sachs Says the Stock Is Overvalued. -- Barrons.com

12 Sept 2025, 15:37 UTC

Market Talk

Gold Holds Near All-Time Highs Ahead of Fed Meeting Next Week -- Market Talk

12 Sept 2025, 15:22 UTC

Market Talk

European Gas Lifted by Geopolitical Risks But Storage Levels Ease Supply Fears -- Market Talk

12 Sept 2025, 15:07 UTC

Acquisitions, Mergers, Takeovers

These Stocks Are Moving the Most Today: Warner Bros., Paramount Skydance, Tesla, Super Micro, Microsoft, Figure Technology, and More -- Barrons.com

Peer Comparison

Price change

10X Genomics Inc (Class A) Forecast

Price Target

By TipRanks

18.04% upside

12 Months Forecast

Average 14.92 USD  18.04%

High 17 USD

Low 13 USD

Based on 13 Wall Street analysts offering 12 month price targets for10X Genomics Inc (Class A) - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

13 ratings

5

Buy

8

Hold

0

Sell

Technical Score

By Trading Central

8.32 / 8.63Support & Resistance

Short Term

Bullish Evidence

Intermediate Term

Bullish Evidence

Long Term

No Evidence

Sentiment

By Acuity

95 / 371 Healthcare

News Sentiment

Bullish Evidence

Volatility

Below average

News Volume (RCV)

Average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About 10X Genomics Inc (Class A)

10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity and networks on a cell-by-cell basis; single cell gene expression flex; single cell immune profiling used to study the immune system; single cell Assay for Transposase Accessible Chromati (ATAC) solution to understand the epigenetic state; and single cell multiome ATAC + gene expression which enables simultaneous interrogation of both the RNA and chromatin accessibility, using ATAC in a single cell. The company also provides Visium platform which enables researchers to understand the spatial positions of biological analytes within tissues at high resolution; and Xenium platform for in situ analysis. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.
help-icon Live chat